Petros Pharmaceuticals amends Series A Preferred Stock redemption and conversion procedures

Petros Pharmaceuticals, Inc.

Filed Certificate of Amendment to Series A Convertible Preferred Stock with Delaware Secretary of State on Sept 29, 2023.
Amendment permits additional procedures for payment of redemptions and conversions.
No change to conversion ratio, dividend rate, or liquidation preference was disclosed.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Petros Pharmaceuticals, Inc.: Amended Certificate of Designations of Series A Convertible Preferred Stock to permit additional procedures for payment of redemptions and conversions (effective 2023-09-29).

Change: charter amendment
Effective: 2023-09-29

Exact text from the filing

On September 29, 2023, Petros Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware (the “Secretary of State”) a Certificate of Amendment of Certificate of Designations of Series A Convertible Preferred Stock (the “Certificate of Amendment”), which became effective upon filing. The Certificate of Amendment amends the Certificate of Designations of Series A Convertible Preferred Stock, previously filed with the Secretary of State on July 14, 2023, to permit certain additional procedures for the payment of redemptions and conversions.

View on SEC.gov

Browse all governance changes →

Petros Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-105624

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.